ADVANCES SERIES · VISION
The Chip That Reads Again: The PRIMA Technology
Some diseases do not switch off all of your sight: they erase exactly the center — a grandchild's face, a line in a book, the number on a bus —. A 2 x 2 millimeter chip under the retina and glasses that project the image onto it are bringing that central vision back to people who had lost it. This is what the study measured, with its full limits.
Educational content prepared with official health sources. Professional medical review pending.
No personalized diagnoses: consult your doctor.
📅 Published November 8, 2026 · 2-minute video · Full transcript included
Watch the direct video (without leaving this page) →
First: what goes dark in geographic atrophy?
The macula is the central zone of the retina: it is what reads, recognizes faces and sees fine detail. In geographic atrophy — the advanced stage of age-related macular degeneration (AMD) — that zone is gradually lost. The vision around it (peripheral vision) remains — the person can find their way around the room and see the furniture — but the center, whatever is right in front of the eyes, is erased. Until recently there was no way to bring that central vision back.
How does the PRIMA system work?
It works in two parts, and both are needed:
- The chip: a photovoltaic sheet 2 x 2 millimeters that a surgeon implants under the retina, at the point where central vision went dark. It is smaller than a fingernail.
- The glasses: special glasses with a camera capture the scene and project it onto the chip. The chip turns that image into an electrical signal that travels along the optic nerve, and the brain receives again what the eye could no longer send on its own.
The vision it returns is central vision, and it works with the glasses on: without the glasses, the chip receives no image to convert.
What the study measured (the real numbers)
The trial is called PRIMAvera and was published in the New England Journal of Medicine on October 20, 2025:
- 38 patients with geographic atrophy from AMD took part.
- At 12 months, the mean improvement was 25.5 letters on the reading chart: more than 5 full lines they could not read before.
- 81 percent achieved a significant improvement (10 letters or more).
- 84 percent were reading letters, numbers and words with the system.
- With longer follow-up, the benefit holds at 3 years, with mean vision near 20/120.
💙 The important care note: the full limits
Stating the limits does not take away hope: it is what lets you ask the right questions at your appointment. It is surgery, and it had serious events: in the trial, serious procedure-related adverse events occurred in 19 of 38 patients; 95 percent were resolved. The vision it returns is central vision, with the glasses on: without the glasses, the chip receives no image to convert — and it is not the full vision from before —. Where it stands today: it received the CE mark in Europe in July 2026; in the United States it is still under FDA evaluation: it is not yet approved and is not sold as a treatment. And it is not for every kind of vision loss: it is for geographic atrophy from macular degeneration. We are not doctors: this is information so you arrive at your appointment prepared.
The question for your appointment
If you or someone in your family is losing the center of their vision, the concrete question for the ophthalmologist is:
"Doctor, is it geographic atrophy from macular degeneration?"
Because if it is, today there is already something to ask about: what options exist, what is coming, and what follow-up your case needs.
Frequently asked questions
Is it approved in the United States yet?
No. The PRIMA system received the CE mark in Europe in July 2026, which authorizes its use there. In the United States it is still under FDA evaluation: it is not yet approved and is not sold as a treatment.
Does it work without the glasses?
No. The chip needs the image the glasses project onto it: without the glasses on, the chip receives nothing to turn into a signal. The vision it returns is central vision, with the glasses.
Does it work for any kind of blindness?
No. What was studied is geographic atrophy from age-related macular degeneration. Other retinal diseases are a different case, reviewed by the specialist.
What risks did the surgery have in the study?
Serious procedure-related adverse events occurred in 19 of 38 patients, and 95 percent were resolved. Every family should know this in full before deciding — which is why it is in this guide, unsweetened —.
References
- PRIMAvera trial, New England Journal of Medicine (October 20, 2025): 38 patients with geographic atrophy from macular degeneration; mean improvement of 25.5 letters at 12 months; 81 percent with significant improvement (10 letters or more); 84 percent reading letters, numbers and words with the system.
- Three-year follow-up of the PRIMA system (Science Corporation): the benefit holds, with mean vision near 20/120.
- Trial safety: serious procedure-related adverse events in 19 of 38 patients; 95 percent were resolved.
- Regulatory status: CE mark in Europe (July 2026). No FDA approval: in the United States the system is still under evaluation and is not sold as a treatment.
How to read this guide: real numbers with their limits — this is a verified advance from a published trial, not a general cure for blindness; the final word on your case belongs to your ophthalmologist, with your studies in hand.
Full video transcript
These letters were erased for her. Today she reads them again, one by one, thanks to a chip smaller than a fingernail, implanted under the retina.
The disease is called geographic atrophy, the advanced stage of macular degeneration. It erases exactly the center of vision: a grandchild's face, a line in a book, the number on a bus. What is around it can still be seen; the center cannot.
The system is called PRIMA, and it works in two parts, both demonstrated on screen. First, the chip: a sheet 2 x 2 millimeters that the surgeon places under the retina, at the exact point where central vision went dark. Second, special glasses: their camera captures the scene and projects it onto the chip, which turns it into a signal for the optic nerve. The brain receives again what the eye could no longer send on its own.
And does it really work? The trial was published in the New England Journal of Medicine, one of the most demanding medical journals in the world. 38 patients took part. At 12 months, the average improvement was 25 letters on the reading chart: more than 5 full lines. 84 percent were reading letters, numbers and words with the system. And at three years, the benefit holds.
The part to hear in full, because it is care: the glasses must be worn — without them, the chip does not work — and the vision it returns is the central vision, not the full vision from before. The surgery had serious events in half of the trial's patients, and 95 percent were resolved. In Europe the system has already received its authorization mark; in the United States it is still under evaluation and is not yet sold.
If someone in your family is losing the center of their vision, this is the question for the appointment: is it geographic atrophy from macular degeneration? Because if it is, today there is already something to ask about. If you want the complete guide to this technology, write INFO and we will send it to you. We are not doctors: this is information so you arrive at your appointment prepared. See you tomorrow.
🎬 Video from Red de Salud Hispana's advances series. Also on YouTube, Facebook, and Instagram.
Want to keep up with real medical advances?
This video is part of our advances series: medical technologies verified in published studies, explained with their numbers and their limits.
Watch all the videos in the series →